• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2022 - 2023年秋冬美国新冠病毒病与流感相关结局比较:一项横断面回顾性研究

Comparison of COVID-19 and Influenza-Related Outcomes in the United States during Fall-Winter 2022-2023: A Cross-Sectional Retrospective Study.

作者信息

Kopel Hagit, Bogdanov Alina, Winer-Jones Jessamine P, Adams Christopher, Winer Isabelle H, Bonafede Machaon, Nguyen Van Hung, Mansi James A

机构信息

Moderna, Inc., Cambridge, MA 02139, USA.

Veradigm, Chicago, IL 60654, USA.

出版信息

Diseases. 2024 Jan 3;12(1):16. doi: 10.3390/diseases12010016.

DOI:10.3390/diseases12010016
PMID:38248367
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10814040/
Abstract

Influenza and COVID-19 contribute significantly to the infectious disease burden during the respiratory season, but their relative burden remains unknown. This study characterizes the frequency and severity of medically attended COVID-19 and influenza during the peak of the 2022-2023 influenza season in the pediatric, adult, and older adult populations and characterizes the prevalence of underlying conditions among patients hospitalized with COVID-19. This cross-sectional analysis included individuals in the Veradigm EHR Database linked to Komodo claims data with a medical encounter between 1 October 2022 and 31 March 2023 (study period). Patients with medical encounters were identified with a diagnosis of COVID-19 or influenza during the study period and stratified based on the highest level of care received with that diagnosis. Among 23,526,196 individuals, there were more COVID-19-related medical encounters than influenza-related encounters, overall and by outcome. Hospitalizations with COVID-19 were more common than hospitalizations with influenza overall (incidence ratio = 4.6) and in all age groups. Nearly all adults hospitalized with COVID-19 had at least one underlying medical condition, but 37.1% of 0-5-year-olds and 25.0% of 6-17-year-olds had no underlying medical conditions. COVID-19 was associated greater burden than influenza during the peak of the 2022-2023 influenza season.

摘要

流感和新冠病毒对呼吸道疾病流行季节的传染病负担有重大影响,但其相对负担仍不明确。本研究描述了2022 - 2023年流感季节高峰期儿科、成人和老年人群中因新冠病毒和流感就医的频率和严重程度,并描述了新冠病毒住院患者潜在疾病的患病率。这项横断面分析纳入了Veradigm电子健康记录数据库中与科莫多理赔数据相关联的个体,这些个体在2022年10月1日至2023年3月31日(研究期间)有过医疗接触。研究期间确定有新冠病毒或流感诊断的有医疗接触的患者,并根据该诊断所接受的最高护理级别进行分层。在23,526,196名个体中,总体及按结果来看,与新冠病毒相关的医疗接触比与流感相关的接触更多。总体而言(发病率比 = 4.6)以及在所有年龄组中,新冠病毒住院比流感住院更常见。几乎所有因新冠病毒住院的成年人都至少有一种基础疾病,但0至5岁儿童中有37.1%、6至17岁儿童中有25.0%没有基础疾病。在2022 - 2023年流感季节高峰期,新冠病毒造成的负担比流感更大。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec78/10814040/ce13654eee8f/diseases-12-00016-g001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec78/10814040/ce13654eee8f/diseases-12-00016-g001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec78/10814040/ce13654eee8f/diseases-12-00016-g001a.jpg

相似文献

1
Comparison of COVID-19 and Influenza-Related Outcomes in the United States during Fall-Winter 2022-2023: A Cross-Sectional Retrospective Study.2022 - 2023年秋冬美国新冠病毒病与流感相关结局比较:一项横断面回顾性研究
Diseases. 2024 Jan 3;12(1):16. doi: 10.3390/diseases12010016.
2
Economic burden and secondary complications of influenza-related hospitalization among adults in the US: a retrospective cohort study.美国成年人因流感相关住院的经济负担和次要并发症:一项回顾性队列研究。
J Med Econ. 2024 Jan-Dec;27(1):324-336. doi: 10.1080/13696998.2024.2314429. Epub 2024 Feb 22.
3
Relative effectiveness of adjuvanted versus non-adjuvanted influenza vaccines in older adults with risk factors for influenza complications during the 2019-2020 U.S. influenza season.2019 - 2020年美国流感季期间,佐剂流感疫苗与非佐剂流感疫苗在有流感并发症风险因素的老年人中的相对有效性。
Vaccine. 2024 Dec 2;42(26):126316. doi: 10.1016/j.vaccine.2024.126316. Epub 2024 Sep 19.
4
Prevalence of SARS-CoV-2 and Influenza Coinfection and Clinical Characteristics Among Children and Adolescents Aged <18 Years Who Were Hospitalized or Died with Influenza - United States, 2021-22 Influenza Season.2021-2022 年流感季美国因流感住院或死亡的<18 岁以下儿童和青少年中 SARS-CoV-2 和流感合并感染的流行率及临床特征。
MMWR Morb Mortal Wkly Rep. 2022 Dec 16;71(50):1589-1596. doi: 10.15585/mmwr.mm7150a4.
5
[Technical guidelines for seasonal influenza vaccination in China (2022-2023)].《中国季节性流感疫苗接种技术指南(2022—2023年)》
Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Oct 6;56(10):1356-1386. doi: 10.3760/cma.j.cn112150-20220825-00840.
6
Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020.2020 年 3 月 1 日至 30 日,14 个州住院的经实验室确诊的 2019 冠状病毒病患者的住院率和特征 - COVID-NET。
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464. doi: 10.15585/mmwr.mm6915e3.
7
Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults.住院美国成年人中呼吸道合胞病毒与 COVID-19 和流感的严重程度比较。
JAMA Netw Open. 2024 Apr 1;7(4):e244954. doi: 10.1001/jamanetworkopen.2024.4954.
8
The Hospital Burden of Flu in Italy: a retrospective study on administrative data from season 2014-2015 to 2018-2019.意大利流感的医院负担:2014-2015 年至 2018-2019 年季节的行政数据回顾性研究。
BMC Infect Dis. 2024 Jun 8;24(1):572. doi: 10.1186/s12879-024-09446-2.
9
[Technical guidelines for seasonal influenza vaccination in China (2021-2022)].《中国季节性流感疫苗接种技术指南(2021—2022年)》
Zhonghua Liu Xing Bing Xue Za Zhi. 2021 Oct 10;42(10):1722-1749. doi: 10.3760/cma.j.cn112338-20210913-00732.
10
COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022.2021 年 1 月至 2022 年 4 月,13 个美国州 18 岁及以上接种和未接种疫苗的成年人因 COVID-19 住院的情况。
JAMA Intern Med. 2022 Oct 1;182(10):1071-1081. doi: 10.1001/jamainternmed.2022.4299.

引用本文的文献

1
Clinical and Paraclinical Peculiarities of SARS-CoV-2 and Influenza Infections in Children: A Comparative Study.儿童感染新型冠状病毒和流感的临床及辅助检查特点:一项对比研究
Life (Basel). 2025 May 14;15(5):784. doi: 10.3390/life15050784.
2
Workplace Vaccination Against COVID-19 and Seasonal Influenza in the United States: A Modeling-Based Estimation of the Health and Economic Benefits for Employers and Employees.美国职场针对新冠病毒和季节性流感的疫苗接种:基于模型对雇主和员工健康及经济效益的评估
J Mark Access Health Policy. 2025 Apr 24;13(2):17. doi: 10.3390/jmahp13020017. eCollection 2025 Jun.
3
Outcomes of non-hospitalized patients with COVID-19 versus seasonal influenza during the fall-winter 2022-2023 period.

本文引用的文献

1
Postacute sequelae of COVID-19 at 2 years.COVID-19 后 2 年的后遗症。
Nat Med. 2023 Sep;29(9):2347-2357. doi: 10.1038/s41591-023-02521-2. Epub 2023 Aug 21.
2
Incidence of New-Onset Hypertension Post-COVID-19: Comparison With Influenza.新冠病毒感染后新发高血压的发病率:与流感的比较。
Hypertension. 2023 Oct;80(10):2135-2148. doi: 10.1161/HYPERTENSIONAHA.123.21174. Epub 2023 Aug 21.
3
Relative Effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines and Homologous Boosting in Preventing COVID-19 in Adults in the US.
2022 - 2023年秋冬季节新冠病毒感染未住院患者与季节性流感患者的结局对比。
BMC Infect Dis. 2025 Mar 31;25(1):442. doi: 10.1186/s12879-025-10833-6.
4
Burden of Acute Respiratory Infections Caused by Influenza Virus, Respiratory Syncytial Virus, and SARS-CoV-2 with Consideration of Older Adults: A Narrative Review.流感病毒、呼吸道合胞病毒和严重急性呼吸综合征冠状病毒2引起的急性呼吸道感染负担:一项纳入老年人的叙述性综述
Infect Dis Ther. 2025 Jan;14(Suppl 1):5-37. doi: 10.1007/s40121-024-01080-4. Epub 2024 Dec 30.
5
Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19-related Hospitalizations and Medical Encounters Among Adults in the United States.2023 - 2024含奥密克戎XBB.1.5的mRNA新冠疫苗(mRNA-1273.815)在美国成年人中预防新冠相关住院和就医的有效性
Open Forum Infect Dis. 2024 Nov 26;11(12):ofae695. doi: 10.1093/ofid/ofae695. eCollection 2024 Dec.
6
Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States.二价(原始毒株/奥密克戎BA.4/BA.5)mRNA新冠疫苗mRNA-1273.222与BNT162b2二价疫苗在美国有基础疾病成年人中的比较效果
Vaccines (Basel). 2024 Sep 27;12(10):1107. doi: 10.3390/vaccines12101107.
7
Navigating the Evolving Landscape of COVID-19: Strategies to Increase Vaccine Confidence and Improve Vaccination Rates in the United States.应对不断演变的新冠疫情形势:美国提高疫苗信心和提升疫苗接种率的策略
Vaccines (Basel). 2024 Sep 19;12(9):1072. doi: 10.3390/vaccines12091072.
BNT162b2、mRNA-1273和Ad26.COV2.S疫苗以及同源加强免疫在美国成年人中预防新冠病毒病的相对有效性
Open Forum Infect Dis. 2023 May 25;10(7):ofad288. doi: 10.1093/ofid/ofad288. eCollection 2023 Jul.
4
Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study.SARS-CoV-2 感染后长达两年的恢复和症状轨迹:基于人群的纵向队列研究。
BMJ. 2023 May 31;381:e074425. doi: 10.1136/bmj-2022-074425.
5
COVID-19 Surveillance After Expiration of the Public Health Emergency Declaration - United States, May 11, 2023.COVID-19 监测在公共卫生紧急事件宣言期满后-美国,2023 年 5 月 11 日。
MMWR Morb Mortal Wkly Rep. 2023 May 12;72(19):523-528. doi: 10.15585/mmwr.mm7219e1.
6
Long COVID Incidence in a Large US Ambulatory Electronic Health Record System.长新冠在大型美国门诊电子健康记录系统中的发病率。
Am J Epidemiol. 2023 Aug 4;192(8):1350-1357. doi: 10.1093/aje/kwad095.
7
Risk of Death in Patients Hospitalized for COVID-19 vs Seasonal Influenza in Fall-Winter 2022-2023.2022 - 2023年秋冬因新冠病毒病住院患者与季节性流感患者的死亡风险
JAMA. 2023 May 16;329(19):1697-1699. doi: 10.1001/jama.2023.5348.
8
The evolution of SARS-CoV-2.严重急性呼吸综合征冠状病毒2的进化
Nat Rev Microbiol. 2023 Jun;21(6):361-379. doi: 10.1038/s41579-023-00878-2. Epub 2023 Apr 5.
9
Risk Factors Associated With Post-COVID-19 Condition: A Systematic Review and Meta-analysis.与新冠后状况相关的风险因素:系统评价和荟萃分析。
JAMA Intern Med. 2023 Jun 1;183(6):566-580. doi: 10.1001/jamainternmed.2023.0750.
10
Comparison of influenza and COVID-19 hospitalisations in British Columbia, Canada: a population-based study.比较加拿大不列颠哥伦比亚省的流感和 COVID-19 住院患者:一项基于人群的研究。
BMJ Open Respir Res. 2023 Feb;10(1). doi: 10.1136/bmjresp-2022-001567.